Skip to main content
Equibles
LONA logo

LONA · LeonaBio, Inc.

Track LONA — free

Use LONA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$7.94 +0.05 (+0.63%) At close · Aug 28
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based upon the Company's current operating plan, it estimates that its $51.1 million of cash, cash equivalents and investments at June 30, 2026 may not be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months which raises substantial doubt as to our ability to continue as a going concern following the date of this Quarterly Report on Form 10-Q.”
View the 10-Q filed Aug 14, 2026
Market Cap
$74.81M
Shares
9.42M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$7.94 Open$8.00 Day$7.94–8.00 Since split$3.62–11.68 Avg vol 30d37K Short int39K · 0.4% float · 3.5d Short vol8% Last earningsAug 14, 2026 DataSep 2025–Aug 2026 Filing10-Q · Aug 14

Raw chart and full-history price indicators begin at the captured split on Sep 18, 2025; bars on opposite sides are not compared.

The closing range begins at the captured split on Sep 18, 2025.

Up next

Next earnings call
Nov 17, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.62
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +7%
above
Price vs 50-day avg −2%
below
RSI (14) 52
neutral
MACD trend Positive
52-week position 54%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +12%
trailing
6-month return +29%
trailing
YTD return +5%
this year
Relative strength +15%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.41% of float · ▼ -4.3% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
44 holders — near 1-yr high, broad support
Squeeze score 41
elevated · 0–100
Fundamentals
Weak
EPS growth +2%
Y/Y
Free cash flow $-45.8M
Quant / Vol
risk profile
Very High
Volatility 109%
annualized · 1-yr
Max drawdown −43%
past year
ATR 6.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 5 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+7% Bullish
Price vs 50-day avg
−2% Neutral
RSI (14)
52 Neutral
MACD trend
Positive Bullish
52-week position
54% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.41% of float · ▼ -4.3% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
44 holders — near 1-yr high, broad support
Price context
position in its range since split · 2025-09-18
Range low $4 Now $8 · 54% Range high $12
vs 200-day avg +7% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LONA
LeonaBio, Inc.
this stock
$74.81M +4.9% — — 0.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.77B +2.9% +20.8% 19.7 2.3%
ARGX
Argenx SE
 $63.63B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.23B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
44
% held
77.2%
Net QoQ
+817.2K sh
Top holder
PERCEPTIVE ADVISORS LLC
Held Float
View
Held by Funds
Fund positions
15
View
Short & Settlement
Short Interest Falling
Shares short
39.0K
Days to cover
3.5d
Change
-1.7K sh
View
Short Volume
Short vol %
8%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
3
Value
$29
As of
Jul 15, 2026
View
Off-Exchange
Off-exchange %
36.3%
Week of
Jul 20, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Christopher L. Jacobs
Amount
$1.0K–$15.0K
Traded
Dec 12, 2022
View
Financials
Financials
Net income (FY)
$-105.6M
EPS diluted
$-24.70
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 26, 2026
This year
13
View
Proposed Sales
Value
$27.7K
Shares
5.2K
Filed
Mar 4, 2026
View
Exempt Offerings
Offering
$90.9M
Filed
Jun 12, 2020
View
Earnings & Events
Earnings Calls
Last call
Aug 14, 2026
View
Investor Relations
Latest news
LeonaBio Reports Second Quarter 2…
Published
Aug 14, 2026
View

Performance

Raw-price comparisons begin at the captured split on Sep 18, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
LONA +3.3% +12.5% +28.7% +12.5% +4.9%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY +2.9% +9.5% +15.3% +9.5% -7.9%
Key facts CIK 1620463 CUSIP 04746L203 13F (30d) 43 filings 42 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)